Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial-Reference-Cited by-同舟云学术

Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial

Published:2013-10 Issue:15 Volume:49 Page:3191-3201
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

van Meurs Hannah S.,Tajik Parvin,Hof Michel H.P.,Vergote Ignace,Kenter Gemma G.,Mol Ben Willem J.,Buist Marrije R.,Bossuyt Patrick M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Ovarian cancer: epidemiology, biology, and prognostic factors;Holschneider;Semin Surg Oncol,2000

2. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004);du Bois;Ann Oncol,2005

3. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N Engl J Med,2010

4. Is the easier way ever the better way?;Chi;J Clin Oncol,2011

5. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree?;Vergote;Gynecol Oncol,2013

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Clinician's perspective on the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer management;Surgical Oncology;2024-10

2. Exosomes-based immunotherapy for cancer: Effective components in the naïve and engineered forms;International Immunopharmacology;2024-09

3. La chirurgie du cancer épithélial avancé de l’ovaire : escalade et désescalade;Bulletin de l'Académie Nationale de Médecine;2024-07

4. Evaluation of short versus long course chemotherapy in the neoadjuvant setting in ovarian cancer;2024-02-13

5. Ovarian Cancer;Biomedical Aspects of Solid Cancers;2024